+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Prediabetes Market Size, Share & Trends Analysis Report by Drug Class (Diguanide, Thiazolidinediones), Age Group (Children, Adult), Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 134 Pages
  • March 2024
  • Region: Global
  • Grand View Research
  • ID: 5950104
Description Jump to:
The global prediabetes market size is anticipated to reach USD 323.83 million by 2030 and it is projected to grow at a CAGR of 7.21% from 2024 to 2030. Several factors drive the market growth. One of the main factors driving is the rising prevalence of prediabetes and increasing obesity rates. Obesity correlates with the development of diabetes. For instance, according to Washington University in St. Louis in June 2023, over 37 million individuals in the U.S. are affected by diabetes, with over 40% of them experiencing obesity, a condition associated with up to half of all diabetes cases. It is estimated that approximately 96 million Americans, constituting roughly one-third of adults, are living with prediabetes. Obesity, often linked with sedentary lifestyles and poor diet, is a significant risk factor for developing prediabetes. The rise in prediabetes cases has coincided with the global obesity epidemic, demonstrating the connection between these two health problems.

Moreover, genetic predisposition and family history also contribute significantly. While lifestyle factors play a predominant role, genetic factors can influence an individual's susceptibility to developing prediabetes, making specific populations more prone to the condition.

Prediabetes Market Report Highlights

  • Based on the drug class, the diguanide segment led the market with the largest revenue share of 83.8% in 2023. Metformin, a drug under the diguanide class is the first choice of drug for the treatment of prediabetes. It is the most commonly prescribed off-label drug for the treatment and slowing down the progression of prediabetes
  • Based on the age group, the adult segment led the market with the largest revenue share of 48.8% in 2023. The increasing sedentary and disease-causing lifestyle among adults is the primary growth factor for this age group segment. The increasing prevalence of prediabetes along with increased awareness are driving the growth of this segment
  • North America dominated the market with the revenue share of 41.50% in 2023, owing to the advanced healthcare infrastructure, high awareness, and high research activities for clinical trials. The region offers an advanced and strong research infrastructure. Community-based programs and support groups empower individuals with prediabetes to make sustainable lifestyle changes, such as healthy eating and regular physical activity


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Drug Class Type Segment
1.1.1.2. Age Group Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Primary Sources
1.11. List of Abbreviations
Chapter 2. Prediabetes Market: Executive Summary
2.1. Market Snapshot
2.2. Drug Class Snapshot
2.3. Age group Type Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Prediabetes Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Increasing global prevalence of prediabetes
3.4.2. Growing awareness and early disease diagnosis due to advanced diagnostic technologies
3.4.3. Favorable government initiatives
3.5. Market Restraint Analysis
3.5.1. Limited FDA-approved treatment options
3.5.2. Regulatory and reimbursement challenges
3.6. Prediabetes Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat of New Entrant
3.6.1.5. Competitive Rivalry
3.6.2. PESTLE Analysis
3.6.2.1. Political Landscape
3.6.2.2. Technological Landscape
3.6.2.3. Economic Landscape
3.6.3. Pricing Analysis
3.6.4. Target Population Analysis
3.6.5. Alternative Medicine Analysis (Qualitative)
3.6.6. Total Addressable Market Analysis
Chapter 4. Prediabetes: Drug Class Estimates & Trend Analysis
4.1. Global Prediabetes Market: Drug Class Segment Dashboard
4.2. Global Prediabetes Market: Drug Class Movement Analysis
4.3. Global Prediabetes Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Diguanide
4.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.5. Thiazolidinediones
4.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.6. Glucagon-like peptide-1 agonists (GLP-1)
4.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.7. SGLT2 inhibitors
4.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.8. DPP-4 inhibitors
4.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.9. Others
4.9.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 5. Prediabetes: Age Group Estimates & Trend Analysis
5.1. Global Prediabetes Market: Age Group Segment Dashboard
5.2. Global Prediabetes Market: Age Group Movement Analysis
5.3. Global Prediabetes Market Size & Trend Analysis, by Age Group, 2018 to 2030 (USD Million)
5.4. Children (12-18 years)
5.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.5. Adults (18-49)
5.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.6. Elderly (50+)
5.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Regional Market Dashboard
6.2. Global Regional Market Snapshot
6.3. Marker Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. U.S.
6.4.1.1. Key Country Dynamics
6.4.1.2. Competitive Scenario
6.4.1.3. Regulatory Framework/Reimbursement Framework
6.4.1.4. U.S. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.4.2. Canada
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework/Reimbursement Framework
6.4.2.4. Canada Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key Country Dynamics
6.5.1.2. Competitive Scenario
6.5.1.3. Regulatory Framework/Reimbursement Framework
6.5.1.4. UK Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.2. Germany
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework/Reimbursement Framework
6.5.2.4. Germany Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.3. Spain
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework/Reimbursement Framework
6.5.3.4. Spain Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework/Reimbursement Framework
6.5.4.4. France Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework/Reimbursement Framework
6.5.5.4. Italy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.6. Denmark
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework/Reimbursement Framework
6.5.6.4. Denmark Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework/Reimbursement Framework
6.5.7.4. Sweden Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.8. Norway
6.5.8.1. Key Country Dynamics
6.5.8.2. Competitive Scenario
6.5.8.3. Regulatory Framework/Reimbursement Framework
6.5.8.4. Norway Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key Country Dynamics
6.6.1.2. Competitive Scenario
6.6.1.3. Regulatory Framework/Reimbursement Framework
6.6.1.4. Japan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6.2. China
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework/Reimbursement Framework
6.6.2.4. China Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6.3. India
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework/Reimbursement Framework
6.6.3.4. India Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6.4. South Korea
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework/Reimbursement Framework
6.6.4.4. South Korea Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework/Reimbursement Framework
6.6.5.4. Thailand Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Competitive Scenario
6.6.6.3. Regulatory Framework/Reimbursement Framework
6.6.6.4. Australia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key Country Dynamics
6.7.1.2. Competitive Scenario
6.7.1.3. Regulatory Framework/Reimbursement Framework
6.7.1.4. Brazil Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.7.2. Mexico
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework/Reimbursement Framework
6.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework/Reimbursement Framework
6.7.3.4. Argentina Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key Country Dynamics
6.8.1.2. Competitive Scenario
6.8.1.3. Regulatory Framework/Reimbursement Framework
6.8.1.4. South Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key Country Dynamics
6.8.2.2. Competitive Scenario
6.8.2.3. Regulatory Framework/Reimbursement Framework
6.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.8.3. UAE
6.8.3.1. Key Country Dynamics
6.8.3.2. Competitive Scenario
6.8.3.3. Regulatory Framework/Reimbursement Framework
6.8.3.4. UAE Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key Country Dynamics
6.8.4.2. Competitive Scenario
6.8.4.3. Regulatory Framework/Reimbursement Framework
6.8.4.4. Kuwait Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company /Competition Categorization
7.2. Participant Overview
7.3. Financial Performance
7.4. Product Overview
7.5. Company Market Share Analysis
7.6. Strategy Mapping, 2023
7.6.1. Novo Nordisk
7.6.1.1. Overview
7.6.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.1.3. Product Benchmarking
7.6.1.4. Strategic Initiatives
7.6.2. Valbiotis
7.6.2.1. Overview
7.6.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.2.3. Product Benchmarking
7.6.2.4. Strategic Initiatives
7.6.3. RESVERLOGIX
7.6.3.1. Overview
7.6.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.3.3. Product Benchmarking
7.6.3.4. Strategic Initiatives
7.6.4. Caelus Health
7.6.4.1. Overview
7.6.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.4.3. Product Benchmarking
7.6.4.4. Strategic Initiatives
7.6.5. SciMar
7.6.5.1. Overview
7.6.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.5.3. Product Benchmarking
7.6.5.4. Strategic Initiatives
7.6.6. Boston Therapeutics
7.6.6.1. Overview
7.6.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.6.3. Product Benchmarking
7.6.6.4. Strategic Initiatives
7.6.7. Aphaia Pharma
7.6.7.1. Overview
7.6.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.7.3. Product Benchmarking
7.6.7.4. Strategic Initiatives
7.6.8. AstraZeneca
7.6.8.1. Overview
7.6.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.8.3. Product Benchmarking
7.6.8.4. Strategic Initiatives
7.6.9. Bristol-Myers Squibb
7.6.9.1. Overview
7.6.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.9.3. Product Benchmarking
7.6.9.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America Prediabetes Market, Region, 2018 - 2030 (USD Million)
Table 3 North America Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 4 North America Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 5 U.S. Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 6 U.S. Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 7 Canada Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 8 Canada Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 9 Europe Prediabetes Market, Region, 2018 - 2030 (USD Million)
Table 10 Europe Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 11 Europe Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 12 UK Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 13 UK Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 14 Germany Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 15 Germany Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 16 France Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 17 France Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 18 Italy Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 19 Italy Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 20 Spain Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 21 Spain Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 22 Sweden Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 23 Sweden Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 24 Norway Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 25 Norway Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 26 Denmark Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 27 Denmark Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 28 Asia Pacific Prediabetes Market, Region, 2018 - 2030 (USD Million)
Table 29 Asia Pacific Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 30 Asia Pacific Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 31 Japan Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 32 Japan Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 33 China Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 34 China Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 35 India Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 36 India Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 37 Australia Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 38 Australia Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 39 South Korea Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 40 South Korea Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 41 Thailand Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 42 Thailand Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 43 Latin America Prediabetes Market, Region, 2018 - 2030 (USD Million)
Table 44 Latin America Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 45 Latin America Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 46 Brazil Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 47 Brazil Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 48 Mexico Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 49 Mexico Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 50 Argentina Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 51 Argentina Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 52 MEA Prediabetes Market, Region, 2018 - 2030 (USD Million)
Table 53 MEA Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 54 MEA Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 55 South Africa Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 56 South Africa Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 59 UAE Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 60 UAE Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
Table 61 Kuwait Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
Table 62 Kuwait Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Data Triangulation Techniques
Fig. 3 Primary Research Pattern
Fig. 4 Primary Interviews in North America
Fig. 5 Primary Interviews in Europe
Fig. 6 Primary Interviews in APAC
Fig. 7 Primary Interviews in Latin America
Fig. 8 Primary Interviews in MEA
Fig. 9 Market Research Approaches
Fig. 10 Value-chain-Based Sizing & Forecasting
Fig. 11 QFD Modeling for Market Share Assessment
Fig. 12 Market Formulation & Validation
Fig. 13 Prediabetes Market: Market Outlook
Fig. 14 Prediabetes Competitive Insights
Fig. 15 Parent Market Outlook
Fig. 16 Related/Ancillary Market Outlook
Fig. 17 Penetration and Growth Prospect Mapping
Fig. 18 Industry Value Chain Analysis
Fig. 19 Prediabetes Market Driver Impact
Fig. 20 Prediabetes Market Restraint Impact
Fig. 21 Prediabetes Market Strategic Initiatives Analysis
Fig. 22 Prediabetes Market: Drug Class Movement Analysis
Fig. 23 Prediabetes Market: Drug Class Outlook and Key Takeaways
Fig. 24 Diguanide Market Estimates and Forecast, 2018 - 2030
Fig. 25 Thiazolidinediones Market Estimates and Forecast, 2018 - 2030
Fig. 26 Glucagon-like peptide-1 agonists (GLP-1) Market Estimates and Forecast, 2018 - 2030
Fig. 27 SGLT2 Inhibitors Market Estimates and Forecast, 2018 - 2030
Fig. 28 DPP-4 Inhibitors Market Estimates and Forecast, 2018 - 2030
Fig. 29 Others Market Estimates and Forecast, 2018 - 2030
Fig. 30 Prediabetes Market: Age Group Movement Analysis
Fig. 31 Prediabetes Market: Age Group Outlook and Key Takeaways
Fig. 32 Children (12-18 years) Market Estimates and Forecasts, 2018 - 2030
Fig. 33 Adults (18-49) Market Estimates and Forecasts, 2018 - 2030
Fig. 34 Elderly (50+) Market Estimates and Forecasts, 2018 - 2030
Fig. 35 Global Prediabetes Market: Regional Movement Analysis
Fig. 36 Global Prediabetes Market: Regional Outlook and Key Takeaways
Fig. 37 Global Prediabetes Market Share and Leading Players
Fig. 38 North America Market Share and Leading Players
Fig. 39 Europe Market Share and Leading Players
Fig. 40 Asia Pacific Market Share and Leading Players
Fig. 41 Latin America Market Share and Leading Players
Fig. 42 Middle East & Africa Market Share and Leading Players
Fig. 43 North America, by Country
Fig. 44 North America Market Estimates and Forecasts, 2018 - 2030
Fig. 45 U.S. Market Estimates and Forecasts, 2018 - 2030
Fig. 46 Canada Market Estimates and Forecasts, 2018 - 2030
Fig. 47 Europe Market Estimates and Forecasts, 2018 - 2030
Fig. 48 UK Market Estimates and Forecasts, 2018 - 2030
Fig. 49 Germany Market Estimates and Forecasts, 2018 - 2030
Fig. 50 France Market Estimates and Forecasts, 2018 - 2030
Fig. 51 Italy Market Estimates and Forecasts, 2018 - 2030
Fig. 52 Spain Market Estimates and Forecasts, 2018 - 2030
Fig. 53 Denmark Market Estimates and Forecasts, 2018 - 2030
Fig. 54 Sweden Market Estimates and Forecasts, 2018 - 2030
Fig. 55 Norway Market Estimates and Forecasts, 2018 - 2030
Fig. 56 Asia Pacific Market Estimates and Forecasts, 2018 - 2030
Fig. 57 China Market Estimates and Forecasts, 2018 - 2030
Fig. 58 Japan Market Estimates and Forecasts, 2018 - 2030
Fig. 59 India Market Estimates and Forecasts, 2018 - 2030
Fig. 60 Thailand Market Estimates and Forecasts, 2018 - 2030
Fig. 61 South Korea Market Estimates and Forecasts, 2018 - 2030
Fig. 62 Australia Market Estimates and Forecasts, 2018 - 2030
Fig. 63 Latin America Market Estimates and Forecasts, 2018 - 2030
Fig. 64 Brazil Market Estimates and Forecasts, 2018 - 2030
Fig. 65 Mexico Market Estimates and Forecasts, 2018 - 2030
Fig. 66 Argentina Market Estimates and Forecasts, 2018 - 2030
Fig. 67 Middle East and Africa Market Estimates and Forecasts, 2018 - 2030
Fig. 68 South Africa Market Estimates and Forecasts, 2018 - 2030
Fig. 69 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
Fig. 70 UAE Market Estimates and Forecasts, 2018 - 2030
Fig. 71 Kuwait Market Estimates and Forecasts, 2018 - 2030
Fig. 72 Market Share of Key Market Players- Prediabetes Market

Companies Mentioned

  • Novo Nordisk
  • Valbiotis
  • RESVERLOGIX
  • Caelus Health
  • SciMar
  • Boston Therapeutics
  • Aphaia Pharma
  • AstraZeneca
  • Bristol-Myers Squibb

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages134
PublishedMarch 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 201.62 Million
Forecasted Market Value ( USD ) by 2030 $ 323.83 Million
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Global Prediabetes Treatment Market Analysis & Forecast to 2024-2034 - Product Image

Global Prediabetes Treatment Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Glucagon-Like Peptide-1 (GLP-1) Agonists Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028) - Product Image

Glucagon-Like Peptide-1 (GLP-1) Agonists Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

  • Report
  • 110 Pages
  • Global
From
Philippines Diabetes Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029 - Product Image

Philippines Diabetes Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

  • Report
  • 70 Pages
  • Philippines
From
Pandemic of Diabetes and Prediabetes: Prevention and Control, An Issue of Endocrinology and Metabolism Clinics of North America. The Clinics: Internal Medicine Volume 50-3 - Product Image

Pandemic of Diabetes and Prediabetes: Prevention and Control, An Issue of Endocrinology and Metabolism Clinics of North America. The Clinics: Internal Medicine Volume 50-3

  • Book
  • North America
Cardiovascular Outcomes of Treatments available for Patients with Type 1 and 2 Diabetes, An Issue of Endocrinology and Metabolism Clinics of North America. The Clinics: Internal Medicine Volume 47-1 - Product Image

Cardiovascular Outcomes of Treatments available for Patients with Type 1 and 2 Diabetes, An Issue of Endocrinology and Metabolism Clinics of North America. The Clinics: Internal Medicine Volume 47-1

  • Book
  • North America

About the Pre Diabetes Drug Market

The Pre Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat pre-diabetes, a condition in which blood sugar levels are higher than normal but not high enough to be classified as diabetes. Pre-diabetes is a risk factor for developing type 2 diabetes, and these drugs are used to help prevent the onset of diabetes. Commonly prescribed pre-diabetes drugs include metformin, acarbose, and glimepiride. These drugs work by increasing insulin sensitivity, reducing glucose production in the liver, and slowing the absorption of glucose from the intestines. Some companies in the Pre Diabetes Drug market include Novo Nordisk, Sanofi, Merck, and Eli Lilly. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.